Hypertension in diabetes: Trends in clinical control in repeated large-scale national surveys from Sweden

Journal of Human Hypertension

Volumn 17, Issue 1, 2003, Pages 37-44

  Nilsson, Peter M ^a   Gudbjornsdottir S ^b   Eliasson, B ^b   Cederholm, J ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Blood pressure; Diabetes; Hypertension; Myocardial infarction; Register; Stroke

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DISEASE CONTROL; FEMALE; HEALTH CARE QUALITY; HEALTH SURVEY; HOSPITAL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEAN ARTERIAL PRESSURE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY HEALTH CARE; QUALITY CONTROL; REGISTER; RISK FACTOR; SAMPLING; SWEDEN; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

ADULT; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; COMORBIDITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH SURVEYS; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; MIDDLE AGED; PROBABILITY; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SWEDEN;

EID: 0037258259     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001503     Document Type: Article

References (25)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
2. Nordlund A et al. Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered. J Intern Med 2001; 250: 57-65.
3. Prevention of coronary risk in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Summary of recommendations. Eur Heart J 1998; 19: 1434-1503.
4. Guidelines Subcomittee. World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
5. Yudkin JS, Chaturvedi N. Developing risk stratification charts for diabetic and non-diabetic patients. Diabetic Med 1999; 16: 219-227.
6. The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
7. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381-389.
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
9. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
10. Alder AI et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 2000; 321: 412-419.
11. Diabetes care and research in Europe: The Saint Vincent declaration. Diabetic Med 1990; 7: 360.
12. Nilsson P et al. Cardiovascular risk factors in treated hypertensives - A nation-wide, cross-sectional study in Sweden. J Intern Med 1993; 233: 239-245.
13. Hypertension in Diabetes Study (HDS): 1. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. The Hypertension in Diabetes Study Group. J Hypertens 1993; 11: 309-317.
14. Andersson D, Lundblad E, Svärdsudd K. A model for early diagnosis of type 2 diabetes mellitus in primary health care. Diabetic Med 1993; 10: 167-173.
15. Wändel P. Risk factors for microvascular and macrovascular complications in men and women with type 2 diabetes. Scand J Prim Health Care 1999; 17: 116-121.
16. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
17. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259.
18. Sawicki PT, Siebenhofer A. Betablocker treatment in diabetes mellitus. J Internal Med 2001; 250: 11-17.
19. Ribacke M, Tibblin G, Rosengren A, Eriksson H. Is hypertension changing? Blood pressure development in cohorts of 50-year-old men between 1963 and 1993. Blood Press 1996; 5: 134-138.
20. McCarron P, Okasha M, McEwen J, Davey Smith G. Changes in blood pressure among students attending Glasgow University between 1948 and 1968: Analyses of cross-sectional surveys. BMJ 2001; 322: 885-889.
21. Colhoun HM et al. The scope for cardiovascular risk factor intervention among people with diabetes mellitus in England: A population-based analysis from the Health Surveys for England 1991-94. Diabetic Med 1999; 16: 35-40.
22. Cederholm J, Nilsson P, for the Q-Heart Study Group. Blood pressure control and other cardiovascular risk factor levels among treated hypertensives in Swedish general practice. Scand J Prim Health Care (in press).
23. Turner RC et al for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316: 823-828.
24. Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25 (supplement 1): S71-S73.
25. Lindholm LH et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 1004-1010.